Tweet
GlaxoSmithKline (GSK) / Tykerb
Good news for women! ... and for men too!
It looks as though GlaxoSmithKline (GSK) may have a home run with this one.
Excerpts:
-------------------------------------
ATLANTA - Women with advanced breast cancer soon may have another treatment option: A novel experimental drug delayed the growth of tumors nearly twice as long as standard chemotherapy did in patients who had stopped responding to Herceptin, doctors reported Saturday.
The experimental drug, Tykerb, worked so well that an international study of it was stopped early, in March, and all participants were offered the drug.
In the study, women who received Tykerb plus the chemotherapy drug Xeloda had no growth of their tumors for an average of 8 1/2 months. That compares to 4 1/2 months for those given only Xeloda, said Dr. Charles Geyer Jr. of Allegheny General Hospital in Pittsburgh.
. . .
"This is huge," said Dr. Roy Herbst, a cancer specialist at the University of Texas' M.D. Anderson Cancer Center in Houston, who had no role in the study but has consulted for Glaxo in the past.
. . .
Tykerb has one big advantage over Herceptin — it's a pill instead of an intravenous drug, which should make it cheaper and easier to use, doctors said.
-------------------------------------
Full story
I say save 'em if ya can!
It looks as though GlaxoSmithKline (GSK) may have a home run with this one.
Excerpts:
-------------------------------------
ATLANTA - Women with advanced breast cancer soon may have another treatment option: A novel experimental drug delayed the growth of tumors nearly twice as long as standard chemotherapy did in patients who had stopped responding to Herceptin, doctors reported Saturday.
The experimental drug, Tykerb, worked so well that an international study of it was stopped early, in March, and all participants were offered the drug.
In the study, women who received Tykerb plus the chemotherapy drug Xeloda had no growth of their tumors for an average of 8 1/2 months. That compares to 4 1/2 months for those given only Xeloda, said Dr. Charles Geyer Jr. of Allegheny General Hospital in Pittsburgh.
. . .
"This is huge," said Dr. Roy Herbst, a cancer specialist at the University of Texas' M.D. Anderson Cancer Center in Houston, who had no role in the study but has consulted for Glaxo in the past.
. . .
Tykerb has one big advantage over Herceptin — it's a pill instead of an intravenous drug, which should make it cheaper and easier to use, doctors said.
-------------------------------------
Full story
I say save 'em if ya can!